PT  - JOURNAL ARTICLE
AU  - Ronchini, Chiara
AU  - Gandini, Sara
AU  - Pasqualato, Sebastiano
AU  - Mazzarella, Luca
AU  - Facciotti, Federica
AU  - Mapelli, Marina
AU  - ,
AU  - Frige, Gianmaria
AU  - Passerini, Rita
AU  - Pase, Luca
AU  - Capizzi, Silvio
AU  - Mastrilli, Fabrizio
AU  - Orecchia, Roberto
AU  - Natoli, Gioacchino
AU  - Pelicci, Pier Giuseppe
TI  - Lower probability and shorter duration of infections after Covid-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs
AID  - 10.1101/2021.09.24.21263978
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.24.21263978
4099  - http://medrxiv.org/content/early/2021/09/27/2021.09.24.21263978.short
4100  - http://medrxiv.org/content/early/2021/09/27/2021.09.24.21263978.full
AB  - The correlation between immune responses and protection from SARS-CoV-2 infections and its duration remains unclear. We performed a sanitary surveillance at the European Institute of Oncology (IEO) in Milan over a 27 months period. Pre-vaccination, in 1493 participants, we scored 266 infections (17.8%) and 8 possible reinfections (3%). Post-vaccination, we identified 30 infections in 2029 vaccinated individuals (1.5%). We report that the probability of infection post-vaccination is i) significantly lower compared to natural infection, ii) associated with a significantly shorter median duration of infection than that of first infection and reinfection, iii) anticorrelated with circulating antibody levels.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Fondazione Europea Guido Venosta, National Instruments Corporation, Ralph Lauren and Fondo MFS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IRB of the European Institute of OncologyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.